Company Snapshot

Investment Thesis

Insulet designs tubeless insulin delivery systems branded as Omnipod, serving type 1 and type 2 diabetics. Automated insulin delivery, international expansion, and GLP-1 coexistence drive growth.

  • Disruptive Form Factor: Wearable patch pumps remove tubing and improve usability.
  • Automation Roadmap: Omnipod 5 integrates CGM data for closed-loop dosing.
  • Scalable Manufacturing: Highly automated plants expand gross margins as volumes climb.

Strategic Mix

U.S. Omnipod Core recurring pod sales
International Omnipod Europe, Canada, and APAC markets
Type 2 Expansion U.S. pharmacy channel targeting MDI conversions
Innovation Pipeline Next-gen hardware, algorithms, and services

Mix follows Insulet's revenue breakdown between U.S., OUS, and new therapy segments.

Recent Performance

MTD TBD
QTD TBD
YTD TBD
5Y TBD

Maxim is cueing up returns data for this security. Once the nightly supported.csv job runs, these metrics will auto-populate.

Strategic Insights

Pharmacy Channel

Payor moves to pharmacy benefit reduce patient friction.

GLP-1 Interaction

Educating physicians shows Omnipod complements incretin therapies.

New Indications

Hospital and gestational diabetes pilots extend TAM.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...